Navigation Links
China Sky One Medical, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2008 Results
Date:4/15/2009

HARBIN, China, April 15 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it will conduct a conference call at 10:00 a.m. Eastern Daylight Time (EDT) on Thursday, April 16, 2009, to discuss its fourth quarter and fiscal year 2008 financial results.

Joining Mr. Yan-qing Liu, Chairman and CEO of China Sky One Medical, Inc., will be Stanley Hao, Chief Financial Officer. The Company plans to issue an earnings announcement prior to the call.

To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (866) 573-1052. International callers should dial (404) 537 - 3305. The Conference ID for this call is 95492620.

If you are unable to participate in the call at this time, a replay will be available for fourteen days starting on Thursday, April 16, 2009 at 12:00 p.m. Eastern Time. To access the replay, dial (800) 642-1687, international callers dial (706) 645-9291 Conference ID 95492620.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (''TDR''), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
    China Sky One Medical, Inc.
     Mr. Yu-Bo Hao, CFO
     Tel:   +86-451-5399-4069
     Email: china_sky_one@yahoo.cn

    Investor Relations Contact:
    CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
2. China Sky One Medical, Inc. Provides Update on Filing Form 10-K
3. China Agri-Business Announces 2008 Operating Results
4. China Biologic Products Announces Strong 2008 Results
5. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
6. China Biologic Products Completes Acquisition of 35% Interest in Xian Huitian Blood Products Co., Ltd.
7. China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results
8. aTyr Pharma to Present at ChinaBio(R) Investor Forum in Hong Kong
9. Niusule Biotech Corp. Formally Establishes a New Venture to Import and Sell Health Foods in the Peoples Republic of China
10. China-Biotics, Inc. Appoints New Chief Financial Officer
11. China Medical Technologies Senior Management Purchased Company Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017 On Thursday, ... session at 5,817.69, down 0.07%; the Dow Jones Industrial ... the S&P 500 closed at 2,345.96, marginally dropping 0.11%. ... closed in green, 4 sectors finished in red, and ... Stock-Callers.com has initiated reports coverage on the following Biotechnology ...
(Date:3/24/2017)... 24, 2017 Agenus Inc. (NASDAQ: AGEN), an ... and cancer vaccines, today announced participation at the following ... William Blair and Maidstone Life Sciences conference "Cancer Immunotherapy ... New York, NY . Agenus will ... at 9:40 am: Robert B. Stein , M.D., ...
(Date:3/23/2017)... ... ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking event company in ... the world, such as Illumina, HP and Qualcomm, and is ranked #1 in its category ... due to its new team building format, a way for teams to not only interact ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):